Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers
10.12779/dnd.2019.18.1.19
- Author:
Yun Jeong HONG
1
;
Kyung Won PARK
;
Do Young KANG
;
Jae Hong LEE
Author Information
1. Department of Neurology, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea.
- Publication Type:Original Article
- Keywords:
Subjective Cognitive Decline;
Alzheimer's Disease;
Neuroimaging Biomarker;
Cognitive Complaint;
Self-reported Questionnaire;
Amyloid PET
- MeSH:
Alzheimer Disease;
Amyloid;
Atrophy;
Biomarkers;
Brain;
Cognition Disorders;
Mass Screening;
Neuroimaging;
Neuropsychological Tests;
Pathology;
Physical Examination;
Plaque, Amyloid;
Positron-Emission Tomography;
White Matter
- From:Dementia and Neurocognitive Disorders
2019;18(1):19-29
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: Subjective cognitive decline (SCD) may be the first symptomatic stage of Alzheimer's disease (AD). Hence, a screening tool to characterize the patients' complaints and assess the risk of AD is required. We investigated the SCD neuroimaging biomarker distributions and the relevance between the self-report questionnaire and Alzheimer's pathologic changes. METHODS: Individuals aged 50 and above with consistent cognitive complaints without any objective cognitive impairments were eligible for the study. The newly developed questionnaire consisted of 2 parts; 10 questions translated from the ‘SCD-plus criteria’ and a Korean version of the cognitive failure questionnaire by Broadbent. All the subjects underwent physical examinations such as blood work, detailed neuropsychological tests, the self-report questionnaire, brain magnetic resonance imagings, and florbetaben positron emission tomography (PET) scans. Amyloid PET findings were interpreted using both visual rating and quantitative analysis. Group comparisons and association analysis were performed using SPSS (version 18.0). RESULTS: A total of 31 participants with SCD completed the study and 25.8% showed positive amyloid depositions. The degree of periventricular white matter hyperintensities (WMH) and hippocampal atrophy were more severe in amyloid-positive SCDs compared to the amyloid-negative group. In the self-reported questionnaire, the ‘informant's report a decline’ and ‘symptom's onset after 65 years of age’ were associated with more Alzheimer's pathologic changes. CONCLUSIONS: Amyloid-positive SCDs differed from amyloid-negative SCDs on WMH, hippocampal atrophy, and a few self-reported clinical features, which gave clues on the prediction of AD pathology.
